RESUMO
BACKGROUND: In this study was assessed the degree of conversion (DC) of amine-free resin cements light cured through lithium disilicate-reinforced ceramics at different thicknesses and translucency. MATERIAL AND METHODS: Specimens were divided into 21 groups (n = 5) according to luting agent used: Variolink Esthetic LC (Light shade), RelyX Ultimate (A1 shade), and Filtek Z350 XT Flow (A1 shade); the ceramic translucency: low (LT) and high (HT); and the ceramic thickness: no ceramic (control), 0.5 mm, 1 mm, and 2 mm. A Teflon mold with (5 x 5 x 0.5 mm) was used to standardize the cement and over it the ceramic block from each group was placed. Set was cured using a polywave LED light (1200 mW/cm2 - Bluephase G2) for 40 s. FTIR spectra of uncured and cured materials was obtained and DC calculated from the height of the peaks 1610 and 1640 cm-1. Data were submitted to ANOVA followed by Tukey's test (α = 0.05). RESULTS: There was a significant difference for luting agents (p< 0.0001) and translucency (p = 0.025), but not for thickness (p = 0.73). Dual amine-free RelyX Ultimate showed the lowest DC values and higher translucency promoted higher DC. CONCLUSIONS: Dual amine-free cement showed the lowest monomer conversion and higher translucency ceramics promoted a higher DC. Key words:Ceramic, degree of conversion, resin cement, thickness, translucency.
RESUMO
A Ciclosporina A é um potente imunossupressor utilizado no tratamento de diversas patologias mediada imunologicamente. É indicado principalmente no tratamento preventivo da rejeição de órgãos em indivíduos transplantados. Efeitos adversos relacionados com o uso do fármaco como a indução de osteopenia, desequilíbrio no processo de remodelação óssea, desenvolvimento de osteoporose e o aumento gengival são descritos na literatura. O objetivo do presente estudo foi revisar através da literatura os efeitos da ciclosporina A no metabolismo do tecido gengival, ósseo e sua influência como possível fator de risco na osseointegração de implantes. Empregando-se os termos cyclosporine AND dental implants; cyclosporine AND osseointegration; e cyclosporine AND gingival overgrowth como palavras chave, foram levantados artigos na base de dados Pubmed, publicados entre os anos de 2000 a 2016, na língua inglesa e portuguesa. Conclui-se que os efeitos adversos causados pela ciclosporina A podem interferir na saúde bucal dos indivíduos e no sucesso do tratamento odontológico. É fundamental que o cirurgião dentista conheça os mecanismos de ação do medicamento, seus efeitos adversos e interações medicamentosas, a fim de desenvolver estratégias de prevenção e tratamento para usuários do medicamento (AU)
Cyclosporine A is a potent immunosuppressive drug used in the treatment of various immunologically mediated pathologies. It is mainly indicated in the preventive treatment of organ rejection in transplant recipients. Adverse effects associated with using the drug such as the induction of osteopenia, imbalance in bone remodeling, development of osteoporosis and gingival enlargement are described in literature. The aim of this study was to review, through literature, the effects of cyclosporine A in the metabolism of gingival tissue, bone and its influence as a possible risk factor in osseointegration of implants. Using the terms cyclosporine AND dental implants; cyclosporine AND osseointegration; and cyclosporine AND gingival overgrowth as keywords, a search was conducted for articles published in the Pubmed database between the years 2000-2016, in English and Portuguese. It was concluded that the adverse effects caused by cyclosporine A may interfere in the oral health of individuals and the success of the dental treatment. It is essential that the dentist is aware of the action mechanisms of the drug, its side effects and medicinal interactions in order to develop prevention and treatment strategies for users of the drug (AU)
